{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:56:14Z","timestamp":1794956174489,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5K08CA270401-02"],"award-info":[{"award-number":["5K08CA270401-02"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Combination radiotherapy (RT) and \u03b1PD-L1 therapy has potential to enhance local and distant (abscopal) tumor control, however, clinical results in humans have been variable. Using murine melanoma models, we found RT\u2009+\u2009\u03b1PD-L1 increases intra-tumor progenitor CD8+\u2009PD-1+\u2009TCF-1+\u2009T cells. This increase depends on trafficking of the PD-1+\u2009TCF-1+ cells from the tumor-draining lymph node (TdLN) to the tumor. RT alone promotes the expansion and differentiation of the TdLN derived PD-1+\u2009TCF-1+ cells into TIM-3+\u2009GZMB+\u2009TCF-1- effector-like cells in the tumor with further enhancement after the addition of \u03b1PD-L1. In the TdLN, combination therapy enriches for a novel PD-1+\u2009TCF-1+\u2009TOX- LY6A+ subset with expression of a type I interferon and migratory signature. This subset is able to traffic to the tumor and differentiate into TIM-3+\u2009TCF-1- cells. Finally, we found that ablation of the PD-1+\u2009TCF-1+\u2009T cell population attenuates the enhanced tumor control observed with combination RT\u2009+\u2009\u03b1PD-L1. These results suggest that abscopal response failures may be secondary to impaired stimulation of TdLN CD8+\u2009PD-1\u2009+\u2009TCF-1+\u2009T cells or an inability of PD-1+\u2009TCF-1+ cells in the TdLN to traffic to the tumor.<\/jats:p>","DOI":"10.1038\/s41467-025-58510-1","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T06:51:01Z","timestamp":1744613461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Combination radiation and \u03b1PD-L1 enhance tumor control by stimulating CD8+\u2009PD-1+\u2009TCF-1+\u2009T cells in the tumor-draining lymph node"],"prefix":"10.1038","volume":"16","author":[{"given":"Yang","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanthi","family":"Chappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6940-9298","authenticated-orcid":false,"given":"Haorui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patan","family":"Tippitak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarralyn","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-9576","authenticated-orcid":false,"given":"Maria","family":"Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Prokhnevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapaola","family":"Mariniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0540-495X","authenticated-orcid":false,"given":"Isabelle","family":"De Bruyker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana S.","family":"Pagadala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8364-7488","authenticated-orcid":false,"given":"Vishal R.","family":"Dhere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-3065","authenticated-orcid":false,"given":"Sarwish","family":"Rafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8297-9643","authenticated-orcid":false,"given":"Aparna H.","family":"Kesarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-3413","authenticated-orcid":false,"given":"Alexandre","family":"Orthwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan N.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad K.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-4587","authenticated-orcid":false,"given":"J. Brandon","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8787-7678","authenticated-orcid":false,"given":"Gregory B.","family":"Lesinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-7352","authenticated-orcid":false,"given":"Michael C.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7624-5598","authenticated-orcid":false,"given":"Haydn","family":"Kissick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0784-2601","authenticated-orcid":false,"given":"Chrystal M.","family":"Paulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0571-3531","authenticated-orcid":false,"given":"Nicole C.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-7264","authenticated-orcid":false,"given":"Zachary S.","family":"Buchwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"58510_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto, M. et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu. Rev. Med. 69, 301\u2013318 (2018).","journal-title":"Annu. Rev. Med."},{"key":"58510_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev. Immunol. 37, 457\u2013495 (2019).","journal-title":"Annu Rev. Immunol."},{"key":"58510_CR3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41590-021-00975-5","volume":"22","author":"MS Abdel-Hakeem","year":"2021","unstructured":"Abdel-Hakeem, M. S. et al. Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. Nat. Immunol. 22, 1008\u20131019 (2021).","journal-title":"Nat. Immunol."},{"key":"58510_CR4","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMsb2300232","volume":"388","author":"PC Johnson","year":"2023","unstructured":"Johnson, P. C., Gainor, J. F., Sullivan, R. J., Longo, D. L. & Chabner, B. Immune checkpoint inhibitors - the need for innovation. N. Engl. J. Med. 388, 1529\u20131532 (2023).","journal-title":"N. Engl. J. Med."},{"key":"58510_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027\u20131034 (2000).","journal-title":"J. Exp. Med."},{"key":"58510_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"58510_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682\u2013687 (2006).","journal-title":"Nature"},{"key":"58510_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-021-03862-z","volume":"597","author":"CS Eberhardt","year":"2021","unstructured":"Eberhardt, C. S. et al. Functional HPV-specific PD-1(+) stem-like CD8 T cells in head and neck cancer. Nature 597, 279\u2013284 (2021).","journal-title":"Nature"},{"key":"58510_CR9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2018.12.034","volume":"176","author":"M Sade-Feldman","year":"2019","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 176, 404 (2019).","journal-title":"Cell"},{"key":"58510_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211.e110 (2019).","journal-title":"Immunity"},{"key":"58510_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"},{"key":"58510_CR12","doi-asserted-by":"publisher","unstructured":"Janopaul-Naylor, J. R., Shen, Y., Qian, D. C. & Buchwald, Z. S. The abscopal effect: a review of pre-clinical and clinical advances. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms222011061 (2021).","DOI":"10.3390\/ijms222011061"},{"key":"58510_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313\u2013322 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"58510_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373\u2013377 (2015).","journal-title":"Nature"},{"key":"58510_CR15","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","volume":"25","author":"L Hammerich","year":"2019","unstructured":"Hammerich, L. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25, 814\u2013824 (2019).","journal-title":"Nat. Med."},{"key":"58510_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53034-6","volume":"15","author":"CS Jansen","year":"2024","unstructured":"Jansen, C. S. et al. Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates. Nat. Commun. 15, 8854 (2024).","journal-title":"Nat. Commun."},{"key":"58510_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","volume":"3","author":"SS Park","year":"2015","unstructured":"Park, S. S. et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol. Res. 3, 610\u2013619 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"58510_CR18","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379\u20135388 (2009).","journal-title":"Clin. Cancer Res."},{"key":"58510_CR19","doi-asserted-by":"publisher","unstructured":"Theelen, W. et al. Effect of Pembrolizumab after stereotactic body radiotherapy vs Pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT Phase 2 randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1478 (2019).","DOI":"10.1001\/jamaoncol.2019.1478"},{"key":"58510_CR20","doi-asserted-by":"crossref","unstructured":"McBride, S. et al. Randomized Phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J. Clin. Oncol. 39, 30\u201337 (2021).","DOI":"10.1200\/JCO.20.00290"},{"key":"58510_CR21","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","volume":"36","author":"JJ Luke","year":"2018","unstructured":"Luke, J. J. et al. Safety and clinical activity of Pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J. Clin. Oncol. 36, 1611\u20131618 (2018).","journal-title":"J. Clin. Oncol."},{"key":"58510_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijrobp.2020.05.022","volume":"108","author":"G Ratnayake","year":"2020","unstructured":"Ratnayake, G. et al. Stereotactic radiation therapy combined with immunotherapy against metastatic melanoma: long-term results of a Phase 1 clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 108, 150\u2013156 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"58510_CR23","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ijrobp.2019.03.041","volume":"104","author":"N Sundahl","year":"2019","unstructured":"Sundahl, N. et al. Phase 2 Trial of Nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma. Int. J. Radiat. Oncol. Biol. Phys. 104, 828\u2013835 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"58510_CR24","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","volume":"24","author":"AE Marciscano","year":"2018","unstructured":"Marciscano, A. E. et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin. Cancer Res. 24, 5058\u20135071 (2018).","journal-title":"Clin. Cancer Res."},{"key":"58510_CR25","doi-asserted-by":"publisher","unstructured":"Buchwald, Z. S. et al. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J. Immunother. Cancer 8 https:\/\/doi.org\/10.1136\/jitc-2020-000867 (2020).","DOI":"10.1136\/jitc-2020-000867"},{"key":"58510_CR26","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","volume":"185","author":"Q Huang","year":"2022","unstructured":"Huang, Q. et al. The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes. Cell 185, 4049\u20134066.e4025 (2022).","journal-title":"Cell"},{"key":"58510_CR27","doi-asserted-by":"publisher","first-page":"E761","DOI":"10.1073\/pnas.1620433114","volume":"114","author":"K Chamoto","year":"2017","unstructured":"Chamoto, K. et al. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc. Natl. Acad. Sci. USA 114, E761\u2013E770 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"58510_CR28","doi-asserted-by":"publisher","unstructured":"Francis, D. M. et al. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci. Transl. Med. 12 https:\/\/doi.org\/10.1126\/scitranslmed.aay3575 (2020).","DOI":"10.1126\/scitranslmed.aay3575"},{"key":"58510_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","volume":"56","author":"N Prokhnevska","year":"2023","unstructured":"Prokhnevska, N. et al. CD8(+) T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity 56, 107\u2013124.e105 (2023).","journal-title":"Immunity"},{"key":"58510_CR30","doi-asserted-by":"publisher","first-page":"eabg7836","DOI":"10.1126\/sciimmunol.abg7836","volume":"6","author":"KA Connolly","year":"2021","unstructured":"Connolly, K. A. et al. A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci. Immunol. 6, eabg7836 (2021).","journal-title":"Sci. Immunol."},{"key":"58510_CR31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1158\/2326-6066.CIR-14-0118","volume":"3","author":"S Chen","year":"2015","unstructured":"Chen, S. et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector\/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol. Res. 3, 149\u2013160 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"58510_CR32","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","volume":"162","author":"S Kleffel","year":"2015","unstructured":"Kleffel, S. et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162, 1242\u20131256 (2015).","journal-title":"Cell"},{"key":"58510_CR33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","volume":"51","author":"WH Hudson","year":"2019","unstructured":"Hudson, W. H. et al. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1(+) Stem-like CD8(+) T cells during chronic infection. Immunity 51, 1043\u20131058.e1044 (2019).","journal-title":"Immunity"},{"key":"58510_CR34","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"58510_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25645-w","volume":"12","author":"M Jergovic","year":"2021","unstructured":"Jergovic, M. et al. Infection-induced type I interferons critically modulate the homeostasis and function of CD8(+) naive T cells. Nat. Commun. 12, 5303 (2021).","journal-title":"Nat. Commun."},{"key":"58510_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev-pathol-031920-093932","volume":"16","author":"GM Boukhaled","year":"2021","unstructured":"Boukhaled, G. M., Harding, S. & Brooks, D. G. Opposing roles of type I interferons in cancer immunity. Annu. Rev. Pathol. 16, 167\u2013198 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"58510_CR37","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41590-022-01262-7","volume":"23","author":"GM Boukhaled","year":"2022","unstructured":"Boukhaled, G. M. et al. Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy. Nat. Immunol. 23, 1273\u20131283 (2022).","journal-title":"Nat. Immunol."},{"key":"58510_CR38","doi-asserted-by":"publisher","unstructured":"Wu, T. et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci. Immunol. 1 https:\/\/doi.org\/10.1126\/sciimmunol.aai8593 (2016).","DOI":"10.1126\/sciimmunol.aai8593"},{"key":"58510_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","volume":"610","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program. Nature 610, 173\u2013181 (2022).","journal-title":"Nature"},{"key":"58510_CR40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee, N. Y. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22, 450\u2013462 (2021).","journal-title":"Lancet Oncol."},{"key":"58510_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31941-w","volume":"13","author":"R Saddawi-Konefka","year":"2022","unstructured":"Saddawi-Konefka, R. et al. Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. Nat. Commun. 13, 4298 (2022).","journal-title":"Nat. Commun."},{"key":"58510_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34676-w","volume":"13","author":"LB Darragh","year":"2022","unstructured":"Darragh, L. B. et al. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat. Commun. 13, 7015 (2022).","journal-title":"Nat. Commun."},{"key":"58510_CR43","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","volume":"42","author":"K Wang","year":"2024","unstructured":"Wang, K. et al. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cells. Cancer Cell 42, 1582\u20131597.e1510 (2024).","journal-title":"Cancer Cell"},{"key":"58510_CR44","doi-asserted-by":"publisher","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/nbt.4314 (2018).","DOI":"10.1038\/nbt.4314"},{"key":"58510_CR45","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/0008-5472.CAN-20-3562","volume":"81","author":"SA Miller","year":"2021","unstructured":"Miller, S. A. et al. LSD1 and Aberrant DNA methylation mediate persistence of enteroendocrine progenitors that support BRAF-Mutant colorectal cancer. Cancer Res. 81, 3791\u20133805 (2021).","journal-title":"Cancer Res."},{"key":"58510_CR46","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","volume":"19","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. & Carmona, S. J. UCell: robust and scalable single-cell gene signature scoring. Comput. Struct. Biotechnol. J. 19, 3796\u20133798 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"58510_CR47","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/bioinformatics\/btab003","volume":"37","author":"J Alquicira-Hernandez","year":"2021","unstructured":"Alquicira-Hernandez, J. & Powell, J. E. Nebulosa recovers single-cell gene expression signals by kernel density estimation. Bioinformatics 37, 2485\u20132487 (2021).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58510-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T06:51:03Z","timestamp":1744613463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58510-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58510"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58510-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3921977\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.C.S. has a consulting role at Checkpoint Surgical, Sensorion, and Synergy Research, Inc, is a member of the advisory board of Regeneron, receives book royalties from Plural Publishing, and has received funding from Astex Pharmaceuticals. G.B.L. has received research funding through a sponsored research agreement between Emory University and Merck and Co., Bristol-Myers Squibb, Boerhinger-Ingelheim, and Vaccinex. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3522"}}